<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OBREDON- hydrocodone bitartrate and guaifenesin solution </strong><br>NOVOTEC PHARMA LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use OBREDON (hydrocodone bitartrate and guaifenesin) Oral Solution safely and effectively. See full prescribing information for OBREDON (hydrocodone bitartrate and guaifenesin) Oral Solution.
 <br><br>
OBREDON (hydrocodone bitartrate and guaifenesin) Oral Solution for oral administration CII
 <br><br>
Initial U.S. Approval: 2014
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">OBREDON Oral Solution is a combination product containing an opioid antitussive and expectorant indicated for: </p>
<ul><li>Symptomatic relief of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and to loosen mucus associated with the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>.</li></ul>
<p class="Highlighta"><span class="Underline">Important Limitations of Use:</span> </p>
<p class="Highlighta">Not indicated for pediatric patients under 18 years of age. (
         
 
    <a href="#S8.4">8.4</a>)
        

    </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Adults and adolescents 18 years of age and older: 10 mL every 4 to 6 hours, not to exceed 6 doses (60 mL) in 24 hours. (
         
 
    <a href="#S2.1">2.1</a>)
        

    </p>
<p class="Highlighta">Measure OBREDON Oral Solution with an accurate milliliter measuring device. (
         
 
    <a href="#S5.9">5.9</a>)
        

    </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Oral Solution: Each 5 mL contains hydrocodone bitartrate, USP, 2.5 mg; and guaifenesin, USP, 200 mg.(
         
 
    <a href="#S3">3</a>)
        

    </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydrocodone bitartrate, guaifenesin, or any of the inactive ingredients of OBREDON Oral Solution. (
          
  
     <a href="#S4">4</a>)
         
 
    </li>
<li>Patients receiving monoamine oxidase inhibitor (MAOI) therapy or within 14 days of stopping such therapy. (
          
  
     <a href="#S4">4</a>)
         
 
    </li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Dose-related <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>: Use with caution. (
          
  
     <a href="#S5.1">5.1</a>)
         
 
    </li>
<li><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span>: Prescribe with caution that is appropriate to the use of other opioids. (
          
  
     <a href="#S5.2">5.2</a>)
         
 
    </li>
<li><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>: Avoid in patients with <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, intracranial lesions or <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>. (
          
  
     <a href="#S5.3">5.3</a>)
         
 
    </li>
<li>Activities requiring mental alertness: Avoid engaging in hazardous tasks requiring complete mental alertness such as driving or operating machinery. (
          
  
     <a href="#S5.4">5.4</a>)
         
 
    </li>
<li>Acute abdominal conditions: Use with caution in patients with acute abdominal conditions. (
          
  
     <a href="#S5.5">5.5</a>)
         
 
    </li>
<li>Coexisting conditions: Use with caution in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, thyroid disease, Addison’s disease, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>, or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. (
          
  
     <a href="#S5.10">5.10</a>)
         
 
    </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions of OBREDON Oral Solution include: </p>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, sedation, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and decreased blood pressure. (
         
 
    <a href="#S6">6</a>)
        

    </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Accelis Pharma at tel: 1-855-461-5100; 
          
  
     <span class="Italics"><a href="http://www.obredon.com/">www.obredon.com</a></span> or FDA at 1-800-FDA-1088; 
          
  
     <span class="Italics"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.
          
  
     </span></span> </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Opioids, antihistamines, antipsychotics, anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> agents, or other CNS depressants (including alcohol): Avoid using with OBREDON Oral Solution; may exhibit additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. (
          
  
     <a href="#S7.1">7.1</a>)
         
 
    </li>
<li>MAO inhibitors (MAOIs) or tricyclic antidepressants: Do not use. May increase the effect of either the antidepressant or hydrocodone. (
          
  
     <a href="#S7.2">7.2</a>)
         
 
    </li>
<li>Anticholinergic drugs: Use with caution in order to avoid <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> and excessive anticholinergic effects. (
          
  
     <a href="#S7.3">7.3</a>)
         
 
    </li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Use with caution in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (
          
  
     <a href="#S8.6">8.6</a>)
         
 
    </li>
<li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: Use with caution in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (
          
  
     <a href="#S8.7">8.7</a>)
         
 
    </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended dosage</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Activities Requiring Mental Alertness</a></h2>
<h2><a href="#section-5.5" class="toc">  5.5 Acute Abdominal Conditions</a></h2>
<h2><a href="#section-5.6" class="toc">  5.6 Co-administration with Anticholinergics</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Co-administration with MAOIs or Tricyclic Antidepressants</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Persistent <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Dosing</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Coexisting Conditions</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Opioids, Antihistamines, Antipsychotics, Anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> Agents, or Other CNS Depressants (Including Alcohol)</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 MAO Inhibitors or Tricyclic Antidepressants</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Anticholinergic Drugs</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse</a></h2>
<h2><a href="#section-9.3" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h2><a href="#section-11.1" class="toc">11.1 Hydrocodone Bitartrate</a></h2>
<h2><a href="#section-11.2" class="toc">11.2 Guaifenesin</a></h2>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">OBREDON Oral Solution is indicated for symptomatic relief of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and to loosen mucus associated with the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>.</p>
<p><span class="Underline">Important Limitations of Use:</span><br>Not indicated for pediatric patients under 18 years of age 
       
 
  <span class="Italics">[see Pediatric Use (
        
  
   <a href="#S8.4">8.4</a>)]
       
 
  </span>.
      

 </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended dosage</h2>
<p class="First"><span class="Underline">Adults and adolescents 18 years of age and older:</span> 10 mL every 4 to 6 hours, not to exceed 6 doses (60 mL) in 24 hours.
        

 </p>
<p>Administer OBREDON Oral Solution by the oral route only. Measure OBREDON Oral Solution with an accurate milliliter measuring device. Do not use a household teaspoon to measure the dose 
         
 
  <span class="Italics">[see Dosing (
          
  
   <a href="#S5.9">5.9</a>)]
         
 
  </span>.
        

 </p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Oral Solution:</p>
<p>Each 5 mL contains hydrocodone bitartrate, USP, 2.5 mg; and guaifenesin, USP, 200 mg 
       
 
  <span class="Italics">[see DESCRIPTION (
        
  
   <a href="#S11">11</a>)]
       
 
  </span>.
      

 </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">OBREDON Oral Solution is contraindicated in:</p>
<ul>
<li>Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydrocodone bitartrate, guaifenesin, or any of the inactive ingredients of OBREDON Oral Solution.</li>
<li>Patients receiving MAOI therapy or within 14 days of stopping such therapy 
        
  
   <span class="Italics">[see DRUG INTERACTIONS (
         
   
    <a href="#S7.2">7.2</a>)].
        
  
   </span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h2>
<p class="First">Hydrocodone bitartrate, one of the active ingredients in OBREDON Oral Solution, produces dose-related <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> by directly acting on brain stem respiratory centers. <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> of hydrocodone bitartrate in adults has been associated with fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and the use of hydrocodone bitartrate in children less than 6 years of age has been associated with fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Exercise caution when administering OBREDON Oral Solution because of the potential for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. If <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> occurs, it may be antagonized by the use of naloxone hydrochloride and other supportive measures when indicated 
         
 
  <span class="Italics">[see OVERDOSAGE (
          
  
   <a href="#S10">10</a>)]
         
 
  </span>.
        

 </p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span></h2>
<p class="First">Hydrocodone can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the morphine type and therefore, has the potential for being abused. Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance may develop upon repeated administration of OBREDON Oral Solution. Prescribe and administer OBREDON Oral Solution with the same degree of caution appropriate to the use of other opioid drugs 
         
 
  <span class="Italics">[see DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span> (
          
  
   <a href="#S9.2">9.2</a>), (
          
  
   <a href="#S9.3">9.3</a>)].
         
 
  </span></p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></h2>
<p class="First">The <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> effects of opioids and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other intracranial lesions, or a pre-existing increase in intracranial pressure. Furthermore, opioids produce adverse reactions which may obscure the clinical course of patients with head injuries. The use of OBREDON Oral Solution should be avoided in these patients.</p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Activities Requiring Mental Alertness</h2>
<p class="First">Hydrocodone bitartrate, one of the active ingredients in OBREDON Oral Solution, may produce marked <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Advise patients to avoid engaging in hazardous tasks requiring mental alertness and motor coordination after ingestion of OBREDON Oral Solution. Concurrent use of OBREDON Oral Solution with alcohol or other central nervous system depressants should be avoided because additional impairment of central nervous system performance may occur.</p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>  5.5 Acute Abdominal Conditions</h2>
<p class="First">OBREDON Oral Solution should be used with caution in patients with acute abdominal conditions since the administration of hydrocodone may obscure the diagnosis or clinical course of patients with acute abdominal conditions. The concurrent use of other anticholinergics with hydrocodone may produce <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> 
         
 
  <span class="Italics">[see DRUG INTERACTIONS (
          
  
   <a href="#S7.3">7.3</a>)].
         
 
  </span></p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>  5.6 Co-administration with Anticholinergics</h2>
<p class="First">The concurrent use of anticholinergics with hydrocodone may produce <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>. Exercise caution when using OBREDON Oral Solution in patients taking anticholinergic medications 
         
 
  <span class="Italics">[see DRUG INTERACTIONS (
          
  
   <a href="#S7.3">7.3</a>)].
         
 
  </span></p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Co-administration with MAOIs or Tricyclic Antidepressants</h2>
<p class="First">OBREDON Oral Solution should not be used in patients receiving MAOI therapy or within 14 days of stopping such therapy. The use of MAOIs or tricyclic antidepressants with hydrocodone bitartrate may increase the effect of either the antidepressant or hydrocodone 
         
 
  <span class="Italics">[see CONTRAINDICATIONS (
          
  
   <a href="#S4">4</a>) and DRUG INTERACTIONS (
          
  
   <a href="#S7.2">7.2</a>)].
         
 
  </span></p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Persistent <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></h2>
<p class="First">OBREDON Oral Solution should not be used in patients with a persistent or <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">chronic cough</span> such as occurs with smoking, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span>, or <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>, or where <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> is accompanied by excessive <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">phlegm</span> (mucus).</p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Dosing</h2>
<p class="First">Patients should be advised to measure OBREDON Oral Solution with an accurate milliliter measuring device. Patients should be informed that a household teaspoon is not an accurate measuring device and could lead to overdosage, which can result in serious adverse reactions 
         
 
  <span class="Italics">[see OVERDOSAGE (
          
  
   <a href="#S10">10</a>)].
         
 
  </span> Patients should be advised to ask their pharmacist to recommend an appropriate measuring device and for instructions for measuring the correct dose.
        

 </p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Coexisting Conditions</h2>
<p class="First">OBREDON Oral Solution should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, thyroid disease, Addison's disease, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>, and <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="S5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">OBREDON Oral Solution should be used with caution in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.
         
 
  <span class="Italics"> [see <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (
          
  
   <a href="#S8.6">8.6</a>)]
         
 
  </span></p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="S5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">OBREDON Oral Solution should be used with caution in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> 
         
 
  <span class="Italics">[see <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (
          
  
   <a href="#S8.7">8.7</a>)].
         
 
  </span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Use of hydrocodone bitartrate is associated with the following:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> 
        
  
   <span class="Italics">[see WARNINGS AND PRECAUTIONS (
         
   
    <a href="#S5.1">5.1</a>) and OVERDOSAGE (
         
   
    <a href="#S10">10</a>)]
        
  
   </span>
</li>
<li><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug dependence</span> 
        
  
   <span class="Italics">[see WARNINGS AND PRECAUTIONS (
         
   
    <a href="#S5.2">5.2</a>) and DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span> (
         
   
    <a href="#S9.3">9.3</a>)]
        
  
   </span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased intracranial pressure</span> 
        
  
   <span class="Italics">[see WARNINGS AND PRECAUTIONS (
         
   
    <a href="#S5.3">5.3</a>)]
        
  
   </span>
</li>
<li>Decreased mental alertness with impaired mental and/or physical abilities 
        
  
   <span class="Italics">[see WARNINGS AND PRECAUTIONS (
         
   
    <a href="#S5.4">5.4</a>)]
        
  
   </span>
</li>
<li><span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">Paralytic ileus</span> 
        
  
   <span class="Italics">[see WARNINGS AND PRECAUTIONS (
         
   
    <a href="#S5.5">5.5</a>)]
        
  
   </span>
</li>
</ul>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The most common adverse reactions experienced by subjects taking a single dose of OBREDON Oral Solution in the clinical setting include the following: Central Nervous System: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation (<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>); Gastrointestinal System: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>; Cardiovascular System: decreased blood pressure; Vascular System: <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No specific interaction studies have been conducted with OBREDON Oral Solution.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Opioids, Antihistamines, Antipsychotics, Anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> Agents, or Other CNS Depressants (Including Alcohol)</h2>
<p class="First">The use of opioids, antihistamines, antipsychotics, anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> agents, or other CNS depressants concomitantly with OBREDON Oral Solution may cause an additive CNS depressant effect and should be avoided.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 MAO Inhibitors or Tricyclic Antidepressants</h2>
<p class="First">Do not prescribe OBREDON Oral Solution if the patient is taking a prescription MAOI (i.e., certain drugs used for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping a MAOI drug. The use of MAOIs or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone 
         
 
  <span class="Italics">[see WARNINGS AND PRECAUTIONS (
          
  
   <a href="#S5.7">5.7</a>)].
         
 
  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Anticholinergic Drugs</h2>
<p class="First">Hydrocodone should be administered cautiously to persons receiving anticholinergic drugs in order to avoid <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> and excessive anticholinergic effects 
         
 
  <span class="Italics">[see WARNINGS AND PRECAUTIONS (
          
  
   <a href="#S5.6">5.6</a>)].
         
 
  </span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Teratogenic Effects:</span> Pregnancy Category C
        

 </p>
<p>There are no adequate and well controlled studies of OBREDON Oral Solution in pregnant women. Reproductive toxicity studies have not been conducted with OBREDON Oral Solution; however, studies are available with an individual active ingredient or related active ingredient. Hydrocodone was teratogenic in hamsters. Codeine, an opiate related to hydrocodone, increased resorptions and decreased fetal weight in rats. Because animal reproduction studies are not always predictive of human response, OBREDON Oral Solution should be used during pregnancy only if the benefit justifies the potential risk to the fetus.</p>
<p><span class="Underline">Hydrocodone:</span></p>
<p>Hydrocodone has been shown to be teratogenic in hamsters when given in a dose approximately 27 times the maximum recommended human daily dose (MRHDD) (on a mg/m
         
 
  <span class="Sup">2</span> basis at a single subcutaneous dose of 102 mg/kg on gestation day 8). Reproductive toxicology studies were also conducted with codeine, an opiate related to hydrocodone. In a study in which pregnant rats were dosed throughout organogenesis, a dose of codeine approximately 40 times the MRHDD of hydrocodone (on a mg/m
         
 
  <span class="Sup">2</span> basis at an oral dose of 120 mg/kg/day of codeine) increased resorptions and decreased fetal weight; however, these effects occurred in the presence of maternal toxicity. In studies in which rabbits and mice were dosed throughout organogenesis, doses of codeine up to approximately 20 and 100 times, respectively, the MRHDD of hydrocodone (on a mg/m
         
 
  <span class="Sup">2</span> basis at oral doses of 30 and 600 mg/kg/day, respectively), produced no adverse developmental effects.
        

 </p>
<p><span class="Italics">Nonteratogenic Effects:</span> Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and excessive <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> reflexes, increased <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, increased stools, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose.
        

 </p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="S8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">As with all opioids, administration of OBREDON Oral Solution to the mother shortly before delivery may result in some degree of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the newborn, especially if higher doses are used.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Caution should be exercised when OBREDON Oral Solution is administered to nursing mothers. Hydrocodone is known to be excreted in human milk. No studies have been performed to determine if guaifenesin is excreted into breastmilk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from OBREDON Oral Solution, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of OBREDON Oral Solution in pediatric patients under 18 years of age has not been established. The use of hydrocodone in children less than 6 years of age is associated with fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> 
         
 
  <span class="Italics">[see WARNINGS AND PRECAUTIONS (
          
  
   <a href="#S5.1">5.1</a>)]
         
 
  </span>.
        

 </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies have not been conducted with OBREDON Oral Solution in geriatric populations. Other reported clinical experience with the individual active ingredients of OBREDON Oral Solution has not identified differences in responses between the elderly and patients younger than 65 years of age. In general, dose selection for an elderly patient should be made with caution, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">OBREDON Oral Solution should be given with caution in patients with severe impairment of renal function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">OBREDON Oral Solution should be given with caution in patients with severe impairment of hepatic function.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="S9"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="S9.1"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
<p class="First">OBREDON Oral Solution is a Schedule II controlled prescription containing hydrocodone bitartrate and should be prescribed and administered with caution.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="S9.2"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse</h2>
<p class="First">Hydrocodone can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the morphine type and therefore, has the potential for being abused. Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance may develop upon repeated administration of OBREDON Oral Solution, and it should be prescribed and administered with the same degree of caution appropriate to the use of other opioid drugs.</p>
<p>Abuse of guaifenesin has been linked to the formation of <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney stones</span> composed of the major metabolite β-(2-methoxyphenoxy) lactic acid.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="S9.3"></a><a name="section-9.3"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance may develop upon repeated administration of opioids; therefore, OBREDON Oral Solution should be prescribed and administered with caution.</p>
<p>Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued oral opioid use, although some mild degree of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> may develop after a few days of opioid therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No human overdosage data are available for OBREDON Oral Solution.</p>
<p><span class="Underline">Hydrocodone</span>:
      

 </p>
<p>Overdosage with hydrocodone is characterized by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (a decrease in <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> and/or tidal volume, Cheyne-Stokes respiration, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>), extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, ringing in the ears, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, eye problems, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, and sometimes <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In severe <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur.</p>
<p><span class="Underline">Guaifenesin</span>:
      

 </p>
<p>Overdosage with guaifenesin can cause <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the central nervous system. While present in polypharmacy <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>, one case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with only significant levels of guaifenesin has been reported. Symptoms included <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, shallow respirations, reduced heart rate with rhythm <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, followed by <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span>.</p>
<p>Treatment of overdosage consists of discontinuation of OBREDON Oral Solution together with institution of appropriate therapy. Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The opioid antagonist naloxone hydrochloride is a specific antidote for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> which may result from overdosage or unusual sensitivity to opioids including hydrocodone. Therefore, an appropriate dose of naloxone hydrochloride should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. For further information, see full prescribing information for naloxone hydrochloride. An antagonist should not be administered in the absence of clinically significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Gastric emptying may be useful in removing unabsorbed drug.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">OBREDON Oral Solution contains hydrocodone bitartrate (a centrally-acting opioid antitussive) and guaifenesin (an expectorant).</p>
<p>Each 5 mL dose of OBREDON Oral Solution contains: hydrocodone bitartrate, USP, 2.5 mg; and guaifenesin, USP, 200 mg.</p>
<p>OBREDON Oral Solution also contains: artificial raspberry flavor, citric acid, glycerin, methylparaben, potassium citrate, potassium sorbate, propylene glycol, propylparaben, purified water, and saccharin sodium.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S11.1"></a><a name="section-11.1"></a><p></p>
<h2>11.1 Hydrocodone Bitartrate</h2>
<p class="First">Hydrocodone Bitartrate is a centrally-acting opioid antitussive and analgesic . It is affected by light and occurs as fine white crystals or crystalline powder which is derived from the opium alkaloid, thebaine. Its chemical name is morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5α)-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1), hydrate (2:5). It is also known as 4,5α-Epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5); and may be represented by the following structural formula:</p>
<div class="Figure"><img alt="HCB Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=31c14c1c-a250-4891-b6ab-9c5961fc8a39&amp;name=figure-01.jpg"></div>
<p class="MultiMediaCaption">C
         
 
  <span class="Sub">18</span>H
         
 
  <span class="Sub">21</span>NO
         
 
  <span class="Sub">3</span> • C
         
 
  <span class="Sub">4</span>H
         
 
  <span class="Sub">6</span>O
         
 
  <span class="Sub">6</span> • 2½H
         
 
  <span class="Sub">2</span>O MW= 494.50
        

 </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S11.2"></a><a name="section-11.2"></a><p></p>
<h2>11.2 Guaifenesin</h2>
<p class="First">Guaifenesin is an expectorant and occurs as a white powder. Its chemical name is 3-(2-methoxyphenoxy)-1,2- propanediol, and may be represented by the following structural formula:</p>
<div class="Figure"><img alt="GFN Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=31c14c1c-a250-4891-b6ab-9c5961fc8a39&amp;name=figure-02.jpg"></div>
<p class="MultiMediaCaption">C
         
 
  <span class="Sub">10</span>H
         
 
  <span class="Sub">14</span>O
         
 
  <span class="Sub">4</span> MW= 198.22
        

 </p>
<p class="MultiMediaCaption"></p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Hydrocodone is a semisynthetic narcotic antitussive and analgesic with multiple actions qualitatively similar to those of codeine. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to act directly on the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> center. In excessive doses, hydrocodone will depress respiration. Hydrocodone can produce <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, and physical and physiological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
<p>Guaifenesin is an expectorant the action of which promotes or facilitates the removal of secretions from the respiratory tract. The precise mechanism of action of guaifenesin is not known; however, it is thought to act as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi. In turn, this may increase the efficiency of the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex and facilitate removal of the secretions.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-12.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Systemic exposure (in terms of peak plasma concentrations and area under plasma concentration versus time curve) of hydrocodone bitartrate and guaifenesin after single dose administration of 10 mL OBREDON Oral Solution are equivalent to respective reference solutions of 5 mL hydrocodone bitartrate (5 mg/5 mL), and 10 mL guaifenesin (200 mg/5 mL).</p>
<p>Hydrocodone: Following a single 10 mL oral dose of OBREDON Oral Solution administered to 36 healthy adults (19-74 years), the geometric mean C
         
 
  <span class="Sub">max</span> and AUC
         
 
  <span class="Sub">0-inf</span> for hydrocodone were 12.6 ng/ml and 80.9 ng·hr/ml, respectively. The median time to maximum concentration for hydrocodone was about 1.25 hours. Food has no significant effect on the extent of absorption of hydrocodone. The mean plasma half-life of hydrocodone is approximately 5 hours.
        

 </p>
<p>Guaifenesin: Following a single 10 mL oral dose of OBREDON Oral Solution administered to 57 healthy adults (19-74 years), the geometric mean Cmax and AUC0-inf for guaifenesin were 3.7 mcg/ml and 4.2 mcg·hr/ml, respectively. The median time to maximum concentration was about 20 minutes. The effect of food on guaifenesin systemic exposure is not considered to be clinically meaningful. The mean plasma half-life of guaifenesin is approximately 1 hour.</p>
<p><span class="Italics"><span class="Underline">Drug interactions</span></span></p>
<p>When guaifenesin and hydrocodone were administered in combination, the pharmacokinetics for each component were similar to those observed when each component was administered separately.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity, mutagenicity, and reproductive studies have not been conducted with OBREDON Oral Solution; however, published information is available for the individual active ingredients or related active ingredients.</p>
<p><span class="Underline">Hydrocodone:</span></p>
<p>Carcinogenicity studies were conducted with codeine, an opiate related to hydrocodone. In 2 year studies in F344/N rats and B6C3F1 mice, codeine showed no evidence of tumorigenicity at dietary doses up to 70 and 400 mg/kg/day, respectively (approximately 23 and 65 times, respectively, the MRHDD of hydrocodone on a mg/m
         
 
  <span class="Sup">2</span> basis).
        

 </p>
<p><span class="Underline">Guaifenesin:</span></p>
<p>Carcinogenicity, genotoxicity, or reproductive toxicology studies have not been conducted with guaifenesin</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Efficacy studies were not conducted with OBREDON Oral Solution. Efficacy of OBREDON Oral Solution is based on demonstration of bioequivalence to the individual comparator products 
       
 
  <span class="Italics">[see CLINICAL PHARMACOLOGY (
        
  
   <a href="#S12.3">12.3</a>)]
       
 
  </span>.
      

 </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">OBREDON Oral Solution is supplied as a clear, raspberry flavored liquid containing 2.5 mg hydrocodone bitartrate and 200 mg guaifenesin in each 5 mL. It is available in:</p>
<p>White HDPE bottles of 16 fl oz. (473 mL): NDC 69166-0523-16 (raspberry flavored)</p>
<p>White HDPE bottles of 4 fl oz. (118 mL): NDC 69166-0523-04 (raspberry flavored)</p>
<p>Store solution at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</p>
<p>Dispense in a tight, light-resistant container, as defined in the USP, with a child-resistant closure.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">[See FDA-Approved Patient Labeling]</span></p>
<p></p>
<p><span class="Underline">Overdosage</span></p>
<p>Advise patients not to increase the dose or dosing frequency of OBREDON Oral Solution because serious adverse events such as <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> may occur with overdosage 
       
 
  <span class="Italics">[see WARNINGS AND PRECAUTIONS (
        
  
   <a href="#S5.1">5.1</a>) and OVERDOSAGE (
        
  
   <a href="#S10">10</a>)].
       
 
  </span></p>
<p></p>
<p><span class="Underline">Dosing</span></p>
<p>Advise patients to measure OBREDON Oral Solution with an accurate milliliter measuring device. Patients should be informed that a household teaspoon is not an accurate measuring device and could lead to overdosage, especially when half a teaspoon is measured. Patients should be advised to ask their pharmacist to recommend an appropriate measuring device and for instructions for measuring the correct dose 
       
 
  <span class="Italics">[see DOSAGE AND ADMINISTRATION (
        
  
   <a href="#S2">2</a>) and WARNINGS AND PRECAUTIONS (
        
  
   <a href="#S5.9">5.9</a>)]
       
 
  </span>.
      

 </p>
<p></p>
<p><span class="Underline">Concomitant Use of Alcohol and Other Central Nervous System Depressants</span></p>
<p>Advise patients to avoid the use of alcohol and other central nervous system depressants while taking OBREDON Oral Solution because additional reduction in mental alertness may occur 
       
 
  <span class="Italics">[see WARNINGS AND PRECAUTIONS (
        
  
   <a href="#S5.4">5.4</a>)].
       
 
  </span></p>
<p></p>
<p><span class="Underline">Activities Requiring Mental Alertness</span></p>
<p>Advise patients to avoid engaging in hazardous tasks that require mental alertness and motor coordination such as operating machinery or driving a motor vehicle as OBREDON Oral Solution may produce marked <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> 
       
 
  <span class="Italics">[see WARNINGS AND PRECAUTIONS (
        
  
   <a href="#S5.4">5.4</a>)].
       
 
  </span></p>
<p></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span></span></p>
<p>Caution patients that OBREDON Oral Solution contains hydrocodone bitartrate and can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> 
       
 
  <span class="Italics">[see WARNINGS AND PRECAUTIONS (
        
  
   <a href="#S5.2">5.2</a>)].
       
 
  </span></p>
<p><span class="Underline">For Medical Information</span></p>
<p>Contact Medical Affairs Department
       
 
  <br>Phone: 1-855-461-5100
            
      

 </p>
<div class="Section" data-sectionCode="42229-5">
<a name="distributor"></a><a name="section-16.1"></a><p></p>
<p class="First">Manufactured for:
         
 
  <br>Accelis Pharma
         
 
  <br>East Windsor, NJ 08520
        

 </p>
<p><img alt="Accelis Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=31c14c1c-a250-4891-b6ab-9c5961fc8a39&amp;name=logo-01.jpg"></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LL1"></a><a name="section-17"></a><p></p>
<h1>Principal Display Panel-16 fl oz. Bottle</h1>
<div class="Figure"><img alt="Principal Display Panel - 16 fl oz. Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=31c14c1c-a250-4891-b6ab-9c5961fc8a39&amp;name=figure-03.jpg"></div>
<p class="First MultiMediaCaption">16 fl oz. Bottle Label</p>
<p>NDC 69166-0523-16</p>
<p><span class="Bold">OBREDON (hydrocodone bitartrate and guaifenesin) Oral Solution CII</span><br>2.5 mg/ 200 mg per 5 mL
      

 </p>
<p><span class="Bold">Contains:</span></p>
<p>Hydrocodone Bitartrate ... 2.5 mg/5 mL
       
 
  <br><span class="Bold">WARNING: May be habit forming.</span></p>
<p>Guaifenesin ..................... 200 mg/5 mL</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">16 fl oz. (473 mL)</span></p>
<p><span class="Bold">USUAL DOSAGE:</span> See Package Insert for Complete Dosage Recommendations.
       
 
  <br>Dispense in a tight, light-resistant container with a child-resistant closure.
      

 </p>
<p><span class="Bold">WARNING: KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</span></p>
<p>Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]</p>
<p>Tamper evident by foil seal under cap. Do not use if foil seal is broken or missing.</p>
<p>Manufactured for:
       
 
  <br>Accelis Pharma
       
 
  <br>East Windsor, NJ 08520
      

 </p>
<p><img alt="Accelis Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=31c14c1c-a250-4891-b6ab-9c5961fc8a39&amp;name=logo-01.jpg"></p>
<p>400822 05/2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LL2"></a><a name="section-18"></a><p></p>
<h1>Principal Display Panel-4 fl oz. Bottle</h1>
<div class="Figure"><img alt="Principal Display Panel - 4 fl oz. Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=31c14c1c-a250-4891-b6ab-9c5961fc8a39&amp;name=figure-04.jpg"></div>
<p class="First MultiMediaCaption">4 fl oz. Bottle Label</p>
<p>NDC 69166-0523-04</p>
<p><span class="Bold">OBREDON (hydrocodone bitartrate and guaifenesin) Oral Solution CII</span><br>2.5 mg/ 200 mg per 5 mL
      

 </p>
<p><span class="Bold">Contains:</span></p>
<p>Hydrocodone Bitartrate ... 2.5 mg/5 mL
       
 
  <br><span class="Bold">WARNING: May be habit forming.</span></p>
<p>Guaifenesin ..................... 200 mg/5 mL</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">4 fl oz. (118 mL)</span></p>
<p><span class="Bold">USUAL DOSAGE:</span> See Package Insert for Complete Dosage Recommendations.
       
 
  <br>Dispense in a tight, light-resistant container with a child-resistant closure.
      

 </p>
<p><span class="Bold">WARNING: KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</span></p>
<p>Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]</p>
<p>Tamper evident by foil seal under cap. Do not use if foil seal is broken or missing.</p>
<p>Manufactured for:
       
 
  <br>Accelis Pharma
       
 
  <br>East Windsor, NJ 08520
      

 </p>
<p><img alt="Accelis Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=31c14c1c-a250-4891-b6ab-9c5961fc8a39&amp;name=logo-01.jpg"></p>
<p>400823 05/2015</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OBREDON 		
					</strong><br><span class="contentTableReg">hydrocodone bitartrate and guaifenesin solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:69166-523</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROCODONE BITARTRATE</strong> (HYDROCODONE) </td>
<td class="formItem">HYDROCODONE BITARTRATE</td>
<td class="formItem">2.5 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>GUAIFENESIN</strong> (GUAIFENESIN) </td>
<td class="formItem">GUAIFENESIN</td>
<td class="formItem">200 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM SORBATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">RASPBERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:69166-523-16</td>
<td class="formItem">473 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:69166-523-04</td>
<td class="formItem">118 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA205474</td>
<td class="formItem">12/30/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>NOVOTEC PHARMA LLC
							(079460110)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sovereign Pharmaceuticals, LLC</td>
<td class="formItem"></td>
<td class="formItem">623168267</td>
<td class="formItem">manufacture(69166-523)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>191d2ee2-9bc4-6d3d-e054-00144ff88e88</div>
<div>Set id: 31c14c1c-a250-4891-b6ab-9c5961fc8a39</div>
<div>Version: 2</div>
<div>Effective Time: 20150622</div>
</div>
</div> <div class="DistributorName">NOVOTEC PHARMA LLC</div></p>
</body></html>
